A once-nightly pill cut breathing interruptions by about 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity. By strengthening the muscles that keep the airway open during sleep, AD109 could offer a new option for people unable to tolerate CPAP.
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/b29951b5-d79c-474c-928a-3b05497816bb)